Related Experiment Video
Updated: May 11, 2025
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
10.9K
Risk Factors Associated with Unsuccessful Dofetilide Initiation Due to Excessive QT Interval Prolongation: A
Johnathon Rast1, Grant Whitebloom1, Omar M Makram1
1Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, USA.
The Journal of Innovations in Cardiac Rhythm Management
|April 18, 2025
Summary
Dofetilide initiation can cause excessive QTc prolongation, particularly in patients with heart failure. This study identified key risk factors, including reduced heart function, suggesting these patients may not tolerate the medication.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dofetilide is a Class III anti-arrhythmic for atrial fibrillation.
- Excessive QTc prolongation is a risk, potentially causing torsades de pointes.
- Current protocols involve inpatient monitoring during initial dofetilide dosing.
Purpose of the Study:
- To identify risk factors for excessive QTc prolongation during dofetilide initiation.
- To investigate associations between comorbidities, echocardiographic values, and QTc prolongation.
Main Methods:
- Single-center retrospective cohort study.
- Analysis of dofetilide initiation in patients with atrial fibrillation.
- Correlation of QTc interval changes with medical history and echocardiographic data.
Main Results:
- Heart failure history, reduced left ventricular ejection fraction, increased left ventricular end-diastolic diameter, increased left atrial diameter, and reduced right ventricular systolic function were significant risk factors.
- Patients with heart failure were less likely to tolerate dofetilide initiation due to QTc prolongation.
Conclusions:
- Specific patient characteristics increase the risk of dofetilide-induced QTc prolongation.
- Heart failure patients may be less tolerant of dofetilide initiation than previously thought, despite its demonstrated safety post-initiation.
More Related Videos
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
808
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
808
01:26Heart Failure Drugs: Inotropic Agents
405
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
405
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
680
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
680
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.0K
01:28Disturbances in Heart Rhythm
710
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
710
01:20Antiepileptic Drugs: Potassium Channel Activators
123
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
123